School of Chinese Medicine, China Medical University, Taichung, Taiwan.
Hepatology. 2010 Nov;52(5):1662-70. doi: 10.1002/hep.23865.
Wilson disease is a copper metabolism disorder caused by mutations in ATP7B, a copper-transporting adenosine triphosphatase. A molecular diagnosis was performed on 135 patients with Wilson disease in Taiwan. We identified 36 different mutations, eight of which were novel: five missense mutations (Ser986Phe, Ile1348Asn, Gly1355Asp, Met1392Lys, and Ala1445Pro), one deletion (2810delT) in the coding region, and two nucleotide substitutions (-133A→C and -215A→T) in the promoter region. These mutations were not observed in 100 control subjects and reduced the activity of the mutated protein by at least 50% when compared with wild-type ATP7B. In addition to exon 8, our data indicate another mutation hotspot in exon 12 where 9.62% of all mutations occurred. An alternative splice variant of ATP7B lacking exon 12 was observed in one patient who had a homozygous 2810delT mutation and very mild clinical symptoms. Clinical examination and functional characterization of alternative splice variants of ATP7B lacking exon 12 showed that they retained 80% of their biological activity. The 2810delT mutation increased the expression of these variants, which may have explained the mild symptoms in the patient with the 2810delT mutation. We also discovered that treating liver cancer cells with a Na(+)/H(+) exchanger inhibitor, 5-(N-ethyl-N-isopropyl)-amiloride, significantly enhanced the expression of the alternative splice variant of ATP7B lacking exon 12.
This study suggests a novel therapeutic strategy for patients with mutations in exon 12.
威尔逊病是一种由 ATP7B 基因突变引起的铜代谢紊乱疾病,ATP7B 是一种铜转运三磷酸腺苷酶。我们对台湾的 135 名威尔逊病患者进行了分子诊断。我们鉴定了 36 种不同的突变,其中 8 种是新的:5 种错义突变(Ser986Phe、Ile1348Asn、Gly1355Asp、Met1392Lys 和 Ala1445Pro)、一个编码区的缺失(2810delT)和两个启动子区域的核苷酸取代(-133A→C 和 -215A→T)。这些突变在 100 名对照中没有观察到,并且与野生型 ATP7B 相比,至少降低了突变蛋白的活性 50%。除了外显子 8,我们的数据还表明另一个突变热点在外显子 12 中,所有突变中有 9.62%发生在外显子 12。在一个具有纯合 2810delT 突变和非常轻微临床症状的患者中观察到缺乏外显子 12 的 ATP7B 的另一种选择性剪接变体。对缺乏外显子 12 的 ATP7B 的替代剪接变体的临床检查和功能特征表明,它们保留了 80%的生物活性。2810delT 突变增加了这些变体的表达,这可能解释了 2810delT 突变患者的轻微症状。我们还发现,用 Na(+)/H(+) 交换器抑制剂 5-(N-乙基-N-异丙基)-阿米洛利处理肝癌细胞,可显著增强缺乏外显子 12 的 ATP7B 的替代剪接变体的表达。
本研究为外显子 12 突变患者提供了一种新的治疗策略。